SBI-087

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSBI-087
Drug Alias NameSBI-087PF-05230895PF-5230895
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[10
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEmergent
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A